The Rise of Regional Dealmaking

Biotechs' drive to retain a bigger chunk of downstream rights is forcing product-hungry Big Pharma to accept non-global licensing deals. They'll be up against existing regional players, more accustomed to sharing rights and prioritizing others' drugs.

Melanie Senior

"We used to hear that partners assumed we wouldn’t be interested [in a licensing deal] if US rights weren’t on...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo